It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer

Pediatric cancer biotech Day One Pharmaceuticals is headed for Nasdaq, in a move that comes less than three months after their work on a brain cancer treatment led to a nine-figure crossover round backed by some blue-chip investors. The South San Francisco-based company is penciling in $100 million as their initial IPO target, though the ultimate raise will likely be higher.